Abstract
Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study
Journal of clinical oncology, Vol.40(16_suppl), pp.4545-4545
06/01/2022
DOI: 10.1200/JCO.2022.40.16_suppl.4545
Abstract
4545
Background: Despite recent advances in the treatment of clear cell RCC, there is a paucity of data to guide management of nccRCC due to the heterogeneity and rarity of these tumors. The clinical activity of combination therapies (including IO-IO, IO-VEGF, VEGF-mTOR) in subtypes of advanced nccRCC is unknown. Methods: In this multicenter retrospective analysis, we evaluated the efficacy of combination systemic therapies in patients with nccRCC. Eligible patients included those with nccRCC as determined by local genitourinary pathology review and receipt of one of three combination regimens during any line treatment (IO-IO, IO-VEGF, mTOR-VEGF). The primary endpoint was objective response rate (ORR) assessed by investigator review. Secondary endpoints were progression- free survival (PFS), disease control rate (DCR), and overall survival (OS). Results: Among 128 included patients, median age was 57 years; 66% were male and 65% white. Histologies included papillary (37%), unclassified (33%), chromophobe (16%), translocation (9%), and other (5 %). Among all patients, 69% had prior nephrectomy; 80% were IMDC intermediate/poor risk; 20% had sarcomatoid and/or rhabdoid differentiation, 27% and 29% had liver and bone metastasis respectively and 63% received combination treatment as first line. Comparison of outcomes based on treatment regimen, line of treatment and subtype is shown in the table. Median PFS and OS were longer with IO/IO and IO/VEGF compared to VEGF/ mTOR at 8.5, 9.5 and 3.7 months and 24.4, 18.2 and 15.4 months respectively. Conclusions: Antitumor activity was observed with novel combinations in nccRCC in both frontline and later line setting. Optimal management of nccRCC remains an unmet need and prospective data is warranted to guide treatment selection for this population. [Table: see text]
Details
- Title: Subtitle
- Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study
- Creators
- Deepak Kilari - Medical College of WisconsinAniko Szabo - Medical College of WisconsinPooja Ghatalia - Fox Chase Cancer CenterTracy L Rose - University of North Carolina at Chapel HillHuaying Dong - Medical College of WisconsinNicole Weise - University of California, San DiegoTony Z. Zhuang - Emory UniversityAbdurahman Alloghbi - The Barbara Ann Karmanos Cancer InstituteRohit K. Jain - Moffitt Cancer CenterAjjai Shivaram Alva - University of Michigan–Ann ArborAbhishek Tripathi - University of Oklahoma Health Sciences CenterArnab Basu - University of Alabama at BirminghamNancy B. Davis - Vanderbilt UniversityJames Brundage - Huntsman Cancer InstituteHamid Emamekhoo - University of Wisconsin–MadisonYousef Zakharia - University of IowaVadim S Koshkin - University of California, San FranciscoMehmet Asim Bilen - Emory UniversityElisabeth I. Heath - The Barbara Ann Karmanos Cancer InstituteRana R. McKay - University of California, San Diego
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.40(16_suppl), pp.4545-4545
- DOI
- 10.1200/JCO.2022.40.16_suppl.4545
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: None.
- Language
- English
- Date published
- 06/01/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548266402771
Metrics
2 Record Views